Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Brad OConnor

  • Home
  •  
  • Brad OConnor



  • Most Read
  • Latest Comments
  • Cogstate buys back exclusive rights to its brain health testing tech from Eisai
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Cogstate buys back exclusive rights to its brain health testing tech from Eisai
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Cogstate buys back exclusive rights to its brain health testing tech from Eisai
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Cogstate buys back exclusive rights to its brain health testing tech from Eisai
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Cogstate buys back exclusive rights to its brain health testing tech from Eisai
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Cogstate buys back exclusive rights to its brain health testing tech from Eisai
    Cogstate buys back exclusive rights to its brain health testing tech from Eisai
    • News

  • New trial results from Actinogen hold promise for Alzheimer’s treatment
    New trial results from Actinogen hold promise for Alzheimer’s treatment
    • News

  • Better than a sudoku: could this drug be the key to preventing Alzheimer’s?
    Better than a sudoku: could this drug be the key to preventing Alzheimer’s?
    • News

  • Cogstate buys back exclusive rights to its brain health testing tech from Eisai
    • News

    Cogstate buys back exclusive rights to its brain health testing tech from Eisai

    Neuroscience tech company Cogstate (ASX: CGS) has re-acquired the global rights to its technology previously exclusively licensed to Japanese pharma company and its global commercial partner, Eisai. The agreement excludes Japan and will come into effect on April 1, 2024. This marks an amendment to the duo’s 2020 agreement, which includes exclusivity across a few

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.